Antisense oligonucleotide therapy in the management of bladder cancer

Current Opinion in Urology

Volumn 15, Issue 5, 2005, Pages 320-327

  So, Alan ^a,b   Rocchi, Palma ^a   Gleave, Martin ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Vancouver Prostate Centre   (Canada)

Author keywords

Antisense oligonucleotide therapy; Bladder cancer; Clusterin; HSP 27

Indexed keywords

AEG 31356; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AP 12009; CGP 69846A; CISPLATIN; CLUSTERIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOXORUBICIN; ETOPOSIDE; GEM 220; GEM 240; GEMCITABINE; GENE EXPRESSION MODULATOR 231; GTI 02051; GTI 2040; HEAT SHOCK PROTEIN 27; ISIS 2503; ISIS 3521; METHOTREXATE; MG 98; OBLIMERSEN; OGX 011; OGX 427; PROTEIN BCL 2; PROTEIN KINASE C ALPHA; PROTEIN MDM2; RAF PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; BLADDER CANCER; BREAST CANCER; CANCER CELL CULTURE; CLINICAL TRIAL; COLON CANCER; CYSTOSCOPY; DRUG DELIVERY SYSTEM; DRUG TARGETING; GENE TARGETING; GENE THERAPY; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; TREATMENT OUTCOME; TUMOR BIOPSY; URINE CYTOLOGY;

EID: 24144493839     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mou.0000175572.46986.2c     Document Type: Review

References (72)

1. Malmstrom PU, Busch C, Norlen BJ. Recurrence, progression and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up. Scand J Urol Nephrol 1987; 21:185-195.
2. Wolf H, Melsen F, Pedersen SE, Nielsen KT. Natural history of carcinoma in situ of the urinary bladder. Scand J Urol Nephrol Suppl 1994; 157:147-151.
3. American Cancer Society. Cancer Facts and Figures 2005. Atlanta, GA: American Cancer Society; 2005, 9-11.
4. Crooke ST. Therapeutic applications of oligonucleotides. Biotechnology (NY) 1992; 10:882-886.
5. Henry S, Stecker K, Brooks D, et al. Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J Pharmacol Exp Ther 2000; 292:468-479.
6. Chi KN, Eisenhauer E, Fazli L, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′methoxyethyl phosphorotioate antisense to clusterin, in patients with prostate cancer prior to radical prostatectomy. J Clin Oncol 2004; 22:3003-3015.
7. Irie A. Advances in gene therapy for bladder cancer. Curr Gene Ther 2003; 3:1-11.
8. Miyake H, Nelson C, Rennie PS, Gleave ME. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000; 60:170-176.
9. Urban E, Noe CR. Structural modifications of antisense oligonucleotides. Farmaco 2003; 58:243-258.
10. Weyermann J, Lochmann D, Zimmer A. Comparison of antisense oligonucleotide drug delivery systems. J Control Release 2004; 100:411-423. This is an excellent review of ASO delivery tools and future technology that may aid the transfection of cells.
11. Weyermann J, Lochmann D, Georgens C, Zimmer A. Albumin-protamine- oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: Cellular uptake and effect. Eur J Pharm Biopharm 2005; 59:431-438.
12. Lochmann D, Weyermann J, Georgens C, et al. Albumin-protamine- oligonucleotide nanoparticles as a new antisense delivery system. Part 1: Physicochemical characterization. Eur J Pharm Biopharm 2005; 59:419-429.
13. Duggan BJ, Cotter FE, Kelly JD, et al. Antisense Bcl-2 oligonucleotide uptake in human transitional cell carcinoma. Eur Urol 2001; 40:685-695.
14. Glackin AJ, Gray SB, Johnston SR, et al. Antisense oligonucleotides in the treatment of bladder cancer. Expert Opin Biol Ther 2005; 5:67-77.
15. Duggan BJ, Gray S, Johnston SR, et al. The role of antisense oligonucleotides in the treatment of bladder cancer. Urol Res 2002; 30:137-147.
16. Duggan BJ, Maxwell P, Kelly JD, et al. The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma. J Urol 2001; 166:1098-1105.
17. Lai J, Gold MS, Kim CS, et al. Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8. Pain 2002; 95:143-152.
18. Maxwell SA, Davis GE. Gene expression profiling of p53-sensitive and -resistant tumor cells using DNA microarray. Apoptosis 2004; 9:171-179. This is an important paper utilizing cDNA microarray to identify genes that are related to p53.
19. Sanchez-Carbayo M, Cordon-Cardo C. Applications of array technology: identification of molecular targets in bladder cancer. Br J Cancer 2003; 89:2172-2177.
20. Rosenberg ME, Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995; 27:633-645.
21. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990; 50:3748-3753.
22. Ho SM, Leav I, Ghatak S, et al. Lack of association between enhanced TRPM-2/clusterin expression and increased apoptotic activity in sex-hormone-induced prostatic dysplasia of the Noble rat. Am J Pathol 1998; 153:131-139.
23. Schwochau GB, Nath KA, Rosenberg ME. Clusterin protects against oxidative stress in vitro through aggregative and nonaggregative properties. Kidney Int 1998; 53:1647-1653.
24. French LE, Sappino AP, Tschopp J, Schifferli JA. Distinct sites of production and deposition of the putative cell death marker clusterin in the human thymus. J Clin Invest 1992; 90:1919-1925.
25. Miyake H, Nelson C, Rennie PS, Gleave ME. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 2000; 141:2257-2265.
26. Zellweger T, Miyake H, July LV, et al. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 2001; 3:360-367.
27. Steinberg J, Oyasu R, Lang S, et al. Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 1997; 3:1707-1711.
28. Miyake H, Gleave M, Kamidono S, Hara I. Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology 2002; 59:150-154.
29. Miyake H, Hara I, Kamidono S, Gleave ME. Synergistic Chemosensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin Cancer Res 2001; 7:4245-4252.
30. Chung J, Kwak C, Jin RJ, et al. Enhanced chemosensitivity of bladder cancer cells to cisplatin by suppression of clusterin in vitro. Cancer Lett 2004; 203:155-161.
31. Miyake H, Eto H, Hara I, et al. Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer KoTCC-1 cells. J Urol 2004; 171:2477-2481. This is an interesting paper utilizing an innovative 'orthotopic' bladder cancer model to assess the efficacy of ASO clusterin in the treatment of bladder cancer.
32. Langer T, Lu C, Echols H, et al. Successive action of DnaK, DnaJ and GroEL along the pathway of chaperone-mediated protein folding. Nature 1992; 356:683-689.
33. Kaufmann SH. Heat shock proteins and the immune response. Immunol Today 1990; 11:129-136.
34. Ellis J. Protein folding. Cytosolic chaperonin confirmed. Nature 1992; 358:191-192.
35. Benjamin IJ. Stress proteins: is their application in clinical medicine on the horizon? Hepatology 1993; 18:1532-1534.
36. Raine CS, Wu E, Ivanyi J, et al. Multiple sclerosis: a protective or a pathogenic role for heat shock protein 60 in the central nervous system? Lab Invest 1996; 75:109-123.
37. Garrido C, Bruey JM, Fromentin A, et al. HSP27 inhibits cytochrome c-dependent activation of procaspase-9. FASEB J 1999; 13:2061-2070.
38. Samali A, Robertson JD, Peterson E, et al. Hsp27 protects mitochondria of thermotolerant cells against apoptotic stimuli. Cell Stress Chaperones 2001; 6:49-58.
39. Concannon CG, Orrenius S, Samali A. Hsp27 inhibits cytochrome c-mediated caspase activation by sequestering both pro-caspase-3 and cytochrome c. Gene Expr 2001; 9:195-201.
40. Lavoie JN, Hickey E, Weber LA, Landry J. Modulation of actin microfilament dynamics and fluid phase pinocytosis by phosphorylation of heat shock protein 27. J Biol Chem 1993; 268:24210-24214.
41. Huot J, Lambert H, Lavoie JN, et al. Characterization of 45-kDa/54-kDa HSP27 kinase, a stress-sensitive kinase which may activate the phosphorylation-dependent protective function of mammalian 27-kDa heat-shock protein HSP27. Eur J Biochem 1995; 227:416-427.
42. Mehlen P, Preville X, Chareyron P, et al. Constitutive expression of human hsp27, Drosophila hsp27, or human alpha B-crystallin confers resistance to TNF- and oxidative stress-induced cytotoxicity in stably transfected murine L929 fibroblasts. J Immunol 1995; 154:363-374.
43. Paul C, Manero F, Gonin S, et al. Hsp27 as a negative regulator of cytochrome C release. Mol Cell Biol 2002; 22:816-834.
44. Cornford PA, Dodson AR, Parsons KF, et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 2000; 60:7099-7105.
45. Love S, King RJ. A 27 kDa heat shock protein that has anomalous prognostic powers in early and advanced breast cancer. Br J Cancer 1994; 69:743-748.
46. Ehrenfried JA, Herron BE, Townsend CM Jr, Evers BM. Heat shock proteins are differentially expressed in human gastrointestinal cancers. Surg Oncol 1995; 4:197-203.
47. Langdon SP, Rabiasz GJ, Hirst GL, et al. Expression of the heat shock protein HSP27 in human ovarian cancer. Clin Cancer Res 1995; 1:1603-1609.
48. Hsu PL, Hsu SM. Abundance of heat shock proteins (hsp89, hsp60, and hsp27) in malignant cells of Hodgkin's disease. Cancer Res 1998; 58:5507-5513.
49. Ciocca DR, Oesterreich S, Chamness GC, et al. Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review. J Natl Cancer Inst 1993; 85:1558-1570.
50. Tomei LD, Kiecolt-Glaser JK, Kennedy S, Glaser R. Psychological stress and phorbol ester inhibition of radiation-induced apoptosis in human peripheral blood, leukocytes. Psychiatry Res 1990; 33:59-71.
51. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351:453-456.
52. Bonkhoff H, Fixemer T, Hunsicker I, Remberger K. Estrogen receptor gene expression and its relation to the estrogen-inducible HSP27 heat shock protein in hormone refractory prostate cancer. Prostate 2000; 45:36-41.
53. Oesterreich S, Weng CN, Qiu M, et al. The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res 1993; 53:4443-4448.
54. Hansen RK, Parra I, Lemieux P, et al. Hsp27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells. Breast Cancer Res Treat 1999; 56:187-196.
55. Garrido C, Fromentin A, Bonnette B, et al. Heat shock protein 27 enhances the tumorigenicity of immunogenic rat colon carcinoma cell clones. Cancer Res 1998; 58:5495-5499.
56. Bruey JM, Paul C, Fromentin A, et al. Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo. Oncogene 2000; 19:4855-4863.
57. Rocchi P, So A, Kojima S, et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004; 64:6595-6602.
58. Somji S, Garrett SG, Sens DA, Sens MA. Heat shock protein 27 expression in human bladder. Urol Pathol 1998; 9:1-15.
59. Rossi MR, Somji S, Garrett SH, et al. Expression of hsp 27, hsp 60, hsc 70, and hsp 70 stress response genes in cultured human urothelial cells (UR-Otsa) exposed to lethal and sublethal concentrations of sodium arsenite. Environ Health Perspect 2002; 110:1225-1232.
60. Kassem H, Sangar V, Cowan R, et al. A potential role of heat shock proteins and nicotinamide N-methyl transferase in predicting response to radiation in bladder cancer. Int J Cancer 2002; 101:454-460.
61. Takashi M, Katsuno S, Sakata T, et al. Different concentrations of two small stress proteins, alphaB crystallin and HSP27 in human urological tumor tissues. Urol Res 1998; 26:395-399.
62. Lebret T, Watson RW, Molinie V, et al. Heat shock proteins HSP27, HSP60, HSP70, and HSP90: expression in bladder carcinoma. Cancer 2003; 98:970-977.
63. Fuessel S, Kueppers B, Ning S, et al. Systematic in vitro evaluation of survivin directed antisense oligodeoxynucleotides in bladder cancer cells. J Urol 2004; 171:2471-2476.
64. Kraemer K, Fuessel S, Kotzsch M, et al. Chemosensitization of bladder cancer cell lines by human telomerase reverse transcriptase antisense treatment. J Urol 2004; 172:2023-2028.
65. Forster Y, Meye A, Krause S, Schwenzer B. Antisense-mediated VEGF suppression in bladder and breast cancer cells. Cancer Lett 2004; 212:95-103.
66. Schaaf A, Sagi S, Langbein S, et al. Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides. Urol Oncol 2004; 22:188-192.
67. Lebedeva I, Raffo A, Rando R, et al. Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides. J Urol 2001; 166:461-469.
68. Ikemoto S, Sugimura K, Kuratukuri K, Nakatani T. Antitumor effects of lipoxygenase inhibitors on murine bladder cancer cell line (MBT-2). Anticancer Res 2004; 24:733-736.
69. Sun HZ, Wu SF, Tu ZH. Blockage of IGF-1R signaling sensitizes urinary bladder cancer cells to mitomycin-mediated cytotoxicity. Cell Res 2001; 11:107-115.
70. Normand N, Valamanesh F, Savoldelli M, et al. VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo. Mol Vis 2005; 11:184-191. This paper describes a novel method of ASO delivery. The development of novel delivery mechanisms will be important in the use of ASO in bladder, eye, and so forth.
71. Shirota H, Sano K, Hirasawa N, et al. B cells capturing antigen conjugated with CpG oligodeoxynucleotides induce Th1 cells by elaborating IL-12. J Immunol 2002; 169:787-794.
72. Ito S, lshii KJ, Gursel M, et al. CpG oligodeoxynucleotides enhance neonatal resistance to Listeria infection. J Immunol 2005; 174:777-782.